In this issue of Blood, Gardner et al report results of a phase 1 trial of 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL) who received a T-cell product of defined CD4/CD8 composition that was genetically modified with a CD19-4-1BB: z chimeric antigen receptor (CAR) lentiviral vector.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Jun 22 2017|
ASJC Scopus subject areas
- Cell Biology